[1]蔡志文,谷涌泉.定向斑块旋切联合药物涂层球囊治疗股腘动脉病变进展 [J].介入放射学杂志,2019,28(03):301-304.
　CAI Zhiwen,GU Yongquan..Directional atherectomy combined with drug- coated balloon dilatation for femoropopliteal artery diseases： recent advances in research[J].journal interventional radiology,2019,28(03):301-304.

点击复制

定向斑块旋切联合药物涂层球囊治疗股腘动脉病变进展
()

PDF下载中关闭

• 
• 
• 

分享到：

参考文献/References:

［1］ Savji N， Rockman CB， Skolnick AH， et al. Association between advanced age and vascular disease in different arterial territories： a population database of over 3.6 million subjects［J］. J Am Coll Cardiol， 2013， 61： 1736- 1743.
［2］ Fowkes FG， Rudan D， Rudan I， et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010： a systematic review and analysis［J］. Lancet， 2013， 382： 1329- 1340.
［3］ Kasapis C， Gurm HS. Current approach to the diagnosis and treatment of femoral- popliteal arterial disease. A systematic review［J］. Curr Cardiol Rev， 2009， 5： 296- 311.
［4］ Garcia L， Jaff MR， Metzger C， et al. Wire- interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries： twelve- month results of the SUPERB trial［J］. Circ Cardiovasc Interv， 2015， 8，pii： e000937.
［5］ Leon LR， Dieter RS， Gadd CL， et al. Preliminary results of the initial United States experience with the supera woven nitinol stent in the popliteal artery［J］. J Vasc Surg， 2013， 57： 1014- 1022.
［6］ Conrad MF， Kang J， Cambria RP， et al. Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease［J］. J Vasc Surg， 2009， 50： 799- 805.
［7］ Vardi M， Novack V， Pencina MJ， et al. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease： a meta- analysis and critical examination of current methodologies［J］. Catheter Cardiovasc Interv， 2014， 83： 975- 983.
［8］ 刘 勇， 刘怡辰． 药物涂层球囊新技术的临床应用进展及述评［J］． 生物医学工程与临床， 2012， 16： 301- 303．
［9］ Chaabane C， Otsuka F， Virmani R， et al. Biological responses in stented arteries［J］. Cardiovasc Res， 2013， 99： 353- 363.
［10］ Yongquan G， Lianrui G， Lixing Q， et al. Plaque excision in the management of lower- limb ischemia of atherosclerosis and in- stent restenosis with the SilverHawk atherectomy catheter［J］. Int Angiol， 2013， 32： 362- 367.
［11］ Quevedo HC， Arain SA， Ali G， et al. A critical view of the peripheral atherectomy data in the treatment of infrainguinal arterial disease［J］. J Invasive Cardiol， 2014， 26： 22- 29.
［12］ Diamantopoulos A， Katsanos K. Atherectomy of the femoropopliteal artery： a systematic review and meta- analysis of randomized controlled trials［J］. J Cardiovasc Surg（Torino）， 2014， 55： 655- 665.
［13］ Zeller T， Krankenberg H， Steinkamp H， et al. One- year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease： the multicenter pathway PVD trial［J］. J Endovasc Ther， 2009， 16： 653- 662.
［14］ Shammas NW. Commentary： the adluminal origin of restenosis in peripheral artery interventions and its implications for the development of future treatment strategies： searching deep into the arterial wall［J］. J Endovasc Ther， 2015， 22： 716- 718.
［15］ 项以力， 张温凯， 杨 镛． 药物涂层球囊和无涂层球囊治疗股腘动脉缺血性疾病疗效及安全性meta分析［J］． 介入放射学杂志， 2017， 26： 500- 507．
［16］ Axel DI， Kunert W， Goggelmann C， et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery［J］. Circulation， 1997， 96： 636- 645.
［17］ Schmidt A， Piorkowski M， Werner M， et al. First experience with drug- eluting balloons in infrapopliteal arteries： restenosis rate and clinical outcome［J］. J Am Coll Cardiol， 2011， 58： 1105- 1109.
［18］ Tellez A， Dattilo R， Mustapha JA， et al. Biological effect of orbital atherectomy and adjunctive paclitaxel- coated balloon therapy on vascular healing and drug retention： early experimental insights into the familial hypercholesterolaemic swine model of femoral artery stenosis［J］. EuroIntervention， 2014， 10： 1002- 1008.
［19］ Tepe G， Zeller T， Albrecht T， et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg［J］. N Engl J Med， 2008， 358： 689- 699.
［20］ Werk M， Albrecht T， Meyer DR， et al. Paclitaxel- coated balloons reduce restenosis after femoro- popliteal angioplasty： evidence from the randomized PACIFIER trial［J］. Circ Cardiovasc Interv， 2012， 5： 831- 840.
［21］ Tepe G， Laird J， Schneider P， et al. Drug- coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease： 12- month results from the IN.PACT SFA randomized trial［J］. Circulation， 2015， 131： 495- 502.
［22］ Scheinert D， Duda S， Zeller T， et al. The LEVANT I （Lutonix paclitaxel- coated balloon for the prevention of femoropopliteal restenosis） trial for femoropopliteal revascularization： first- in- human randomized trial of low- dose drug- coated balloon versus uncoated balloon angioplasty［J］. JACC Cardiovasc Interv， 2014， 7： 10- 19.
［23］ Rosenfield K， Jaff MR， White CJ， et al. Trial of a paclitaxel- coated balloon for femoropopliteal artery disease［J］. N Engl J Med， 2015， 373： 145- 153.
［24］ Fanelli F， Cannavale A， Boatta E， et al. Lower limb multilevel treatment with drug- eluting balloons： 6- month results from the DEBELLUM randomized trial［J］. J Endovasc Ther， 2012， 19： 571- 580.
［25］ Liistro F， Grotti S， Porto I， et al. Drug- eluting balloon in peripheral intervention for the superficial femoral artery： the DEBATE- SFA randomized trial（drug eluting balloon in peripheral intervention for the superficial femoral artery）［J］. JACC Cardiovasc Interv， 2013， 6： 1295- 1302.
［26］ Bausback Y， Willfort- Ehringer A， Sievert H， et al. Six- month results from the initial randomized study of the ranger paclitaxel- coated balloon in the femoropopliteal segment［J］. J Endovasc Ther， 2017， 24： 459- 467.
［27］ Jia X， Zhang J， Zhuang B， et al. Acotec drug- coated balloon catheter： randomized， multicenter， controlled clinical study in femoropopliteal arteries： evidence from the acoArt I trial［J］. JACC Cardiovasc Interv， 2016， 9： 1941- 1949.
［28］ Tepe G， Zeller T， Schnorr B， et al. High- grade， non- flow- limiting dissections do not negatively impact long- term outcome after paclitaxel- coated balloon angioplasty： an additional analysis from the THUNDER study［J］. J Endovasc Ther， 2013， 20： 792- 800.
［29］ Tepe G， Beschorner U， Ruether C， et al. Drug- eluting balloon therapy for femoropopliteal occlusive disease： predictors of outcome with a special emphasis on calcium［J］. J Endovasc Ther， 2015， 22： 727- 733.
［30］ Beschorner U， Zeller T. Combination of mechanical atherectomy and drug- eluting balloons for femoropopliteal in- stent restenosis［J］. J Cardiovasc Surg（Torino）， 2014， 55： 347- 349.
［31］ Cioppa A， Stabile E， Popusoi G， et al. Combined treatment of heavy calcified femoro- popliteal lesions using directional atherectomy and a paclitaxel coated balloon： one- year single centre clinical results［J］. Cardiovasc Revasc Med， 1900， 13： 219- 223.
［32］ Sixt S， Carpio Cancino OG， Treszl A， et al. Drug- coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries［J］. J Vasc Surg， 2013， 58： 682- 686.
［33］ Zeller T， Langhoff R， Rocha- Singh KJ， et al. Directional atherectomy followed by a paclitaxel- coated balloon to inhibit restenosis and maintain vessel patency： twelve- month results of the DEFINITIVE AR study［J］. Circ Cardiovasc Interv， 2017， 10，pii： e004848.
［34］ Stavroulakis K， Schwindt A， Torsello G， et al. Directional atherectomy with antirestenotic therapy vs drug- coated balloon angioplasty alone for isolated popliteal artery lesions［J］. J Endovasc Ther， 2017， 24： 181- 188.